NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis $3.98 -0.07 (-1.73%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$3.86▼$4.0450-Day Range$0.59▼$6.9052-Week Range$3.79▼$10.40Volume8,501 shsAverage Volume15,831 shsMarket Capitalization$164.04 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Evogene alerts: Email Address Evogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside364.8% Upside$18.50 Price TargetShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.50 out of 5 starsMedical Sector715th out of 924 stocksAgricultural Chemicals Industry9th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has received no research coverage in the past 90 days.Read more about Evogene's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.60% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently increased by 864.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVGN. Previous Next 1.7 News and Social Media Coverage News SentimentEvogene has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Evogene this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Evogene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions.Read more about Evogene's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Evogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Evogene Stock (NASDAQ:EVGN)Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Read More EVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVGN Stock News HeadlinesAugust 22 at 7:00 AM | prnewswire.comEvogene Reports Second Quarter 2024 Financial ResultsAugust 21 at 12:57 PM | msn.comEvogene Q2 2024 Earnings PreviewAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 20 at 2:27 AM | americanbankingnews.comEvogene (EVGN) Set to Announce Earnings on ThursdayAugust 12, 2024 | prnewswire.comEvogene Regains Compliance with Nasdaq Minimum Closing Bid Price RuleAugust 12, 2024 | prnewswire.comEvogene Schedules Second Quarter 2024 Financial Results ReleaseJuly 31, 2024 | prnewswire.comCasterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in BrazilJuly 24, 2024 | nz.finance.yahoo.comEvogene Ltd. (EVGN.TA)August 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. July 23, 2024 | msn.comEvogene to effect 1-for-10 reverse stock splitJuly 23, 2024 | prnewswire.comEvogene Announces Expected Implementation of 1-for-10 Reverse Share SplitJuly 17, 2024 | prnewswire.comICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-StimulantsJuly 2, 2024 | prnewswire.comLavie Bio Announces Commercial Expansion of Yalos™ to Winter WheatJune 25, 2024 | prnewswire.comCasterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African CountryMay 23, 2024 | investorplace.comEVGN Stock Earnings: Evogene Beats EPS, Beats Revenue for Q1 2024May 23, 2024 | prnewswire.comBiomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & MelanomaMay 23, 2024 | prnewswire.comEvogene Reports First Quarter 2024 Financial ResultsMay 21, 2024 | prnewswire.comCasterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor SeedsSee More Headlines Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today8/22/2024Next Earnings (Confirmed)8/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Agricultural chemicals Sub-IndustryChemicals Current SymbolNASDAQ:EVGN CUSIPN/A CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$18.50 Low Stock Price Target$18.50 Potential Upside/Downside+364.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,880,000.00 Net Margins-233.66% Pretax Margin-248.19% Return on Equity-70.96% Return on Assets-41.10% Debt Debt-to-Equity RatioN/A Current Ratio5.06 Quick Ratio4.94 Sales & Book Value Annual Sales$9.19 million Price / Sales17.85 Cash FlowN/A Price / Cash FlowN/A Book Value$6.96 per share Price / Book0.57Miscellaneous Outstanding Shares41,216,000Free Float38,166,000Market Cap$164.04 million OptionableOptionable Beta1.40 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Ofer Haviv CPA (Age 58)CEO & President Comp: $390kDr. Nir Arbel (Age 44)Chief Product Officer Comp: $228kDr. Brian Ember (Age 48)Chief Executive Officer of AgPlenus Ltd Comp: $287kDr. Elran Hillel Haber M.B.A. (Age 44)Ph.D., Chief Executive Officer of Biomica Ltd Comp: $302kMr. Amit Noam Capt. res. (Age 42)Chief Executive Officer of Lavie Bio Ltd. Comp: $136kMr. Yaron Eldad (Age 59)Chief Financial Officer Mr. Mark Kapel (Age 47)Chief Technology Officer Comp: $276kRachel Pomerantz GerberHead of Investor RelationsMr. Sassi Masliah (Age 45)Vice President of Corporate Development Comp: $245kMs. Liat Foigel WejgmanVice President of Human ResourcesMore ExecutivesKey CompetitorsAmerican VanguardNYSE:AVDMarrone Bio InnovationsNASDAQ:MBIIValhiNYSE:VHILuxferNYSE:LXFRARQNASDAQ:ARQView All Competitors EVGN Stock Analysis - Frequently Asked Questions How have EVGN shares performed this year? Evogene's stock was trading at $8.40 at the beginning of the year. Since then, EVGN stock has decreased by 52.6% and is now trading at $3.98. View the best growth stocks for 2024 here. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) posted its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($1.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $0.10. The biotechnology company had revenue of $0.58 million for the quarter, compared to analyst estimates of $1.73 million. Evogene had a negative net margin of 233.66% and a negative trailing twelve-month return on equity of 70.96%. When did Evogene's stock split? Evogene's stock reverse split on Thursday, July 25th 2024. The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). This page (NASDAQ:EVGN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
